New Dual-Target Drug Fights Brain Tumors Without Harming Intellect

A new generation of oral dual-target inhibitors is offering hope to middle-aged adults in Taiwan diagnosed with low-grade gliomas, a type of brain tumor that commonly affects individuals in their prime working years.

Chimei Hospital has introduced this innovative treatment, which targets specific gene mutations, namely IDH1 or IDH2, found in approximately 70% to 80% of low-grade glioma patients. These mutations disrupt normal brain cell differentiation and accelerate tumor growth. The drug is designed to penetrate the blood-brain barrier, precisely targeting and blocking the abnormal cancer signals.

“

the hospital has introduced a new generation of oral dual-target inhibitors that can combat low-grade gliomas, which are common in middle-aged and young adults, without damaging brain intelligence.

Dr. Yen Shih-tao, a neurosurgery specialist at Chimei Hospital, explained that the drug, based on the international Phase III INDIGO clinical trial, has shown a significant reduction in disease progression or death risk by over 61%. This allows patients to delay radiation and chemotherapy, potentially preserving brain function and maintaining a better quality of life.

“

This new drug can lower the risk of disease progression or death by more than 61%, helping to delay the time for radiation and chemotherapy, giving patients the opportunity to control the tumor while preserving brain function and quality of life.

Gliomas account for nearly 80% of all primary malignant brain tumors, with low-grade gliomas often occurring between the ages of 30 and 44. Their infiltrative growth pattern makes complete surgical removal extremely difficult, leading to a high risk of recurrence or progression to higher-grade tumors within five years. Patients often present with initial symptoms like seizures, significantly impacting their careers and families.

Previously, patients faced a difficult choice between early chemotherapy and radiation, which can cause severe side effects like myelosuppression, immune deficiency, fatigue, and irreversible cognitive decline, or watchful waiting, which risks tumor progression. The new dual-target inhibitor offers a precise treatment option that aims to control the tumor while preserving cognitive abilities and overall life quality for patients during their most productive years.

“

About 70% to 80% of low-grade glioma patients carry IDH1 or IDH2 gene mutations, which block the normal differentiation of brain cells and accelerate tumor growth.